NOT FOR DISTRIBUTION
Header cover image

Market Cap

US$19.7b

Last Updated

2021/05/13 23:46 UTC

Data Sources

Company Financials +

Executive Summary

Horizon Therapeutics Public Limited Company focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. More Details


Snowflake Analysis

High growth potential with adequate balance sheet.


Similar Companies

Share Price & News

How has Horizon Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: HZNP is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: HZNP's weekly volatility (7%) has been stable over the past year.


Market Performance


7 Day Return

-2.4%

HZNP

-1.5%

US Biotechs

-2.8%

US Market


1 Year Return

95.8%

HZNP

19.7%

US Biotechs

49.0%

US Market

Return vs Industry: HZNP exceeded the US Biotechs industry which returned 19.2% over the past year.

Return vs Market: HZNP exceeded the US Market which returned 49.4% over the past year.


Shareholder returns

HZNPIndustryMarket
7 Day-2.4%-1.5%-2.8%
30 Day-4.2%-0.3%-2.6%
90 Day-3.1%-12.2%-1.5%
1 Year95.8%95.8%21.6%19.7%51.5%49.0%
3 Year482.2%482.2%23.1%16.9%58.2%48.3%
5 Year500.5%500.5%51.0%39.3%123.8%98.9%

Long-Term Price Volatility Vs. Market

How volatile is Horizon Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Horizon Therapeutics undervalued compared to its fair value and its price relative to the market?

44.3%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: HZNP ($87.74) is trading below our estimate of fair value ($157.59)

Significantly Below Fair Value: HZNP is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: HZNP is poor value based on its PE Ratio (66.6x) compared to the US Biotechs industry average (25.7x).

PE vs Market: HZNP is poor value based on its PE Ratio (66.6x) compared to the US market (19.5x).


Price to Earnings Growth Ratio

PEG Ratio: HZNP is good value based on its PEG Ratio (0.9x)


Price to Book Ratio

PB vs Industry: HZNP is overvalued based on its PB Ratio (5.1x) compared to the US Biotechs industry average (3.3x).


Future Growth

How is Horizon Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 11 analysts?

71.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: HZNP's forecast earnings growth (71.2% per year) is above the savings rate (2%).

Earnings vs Market: HZNP's earnings (71.2% per year) are forecast to grow faster than the US market (14.7% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: HZNP's revenue (14.8% per year) is forecast to grow faster than the US market (9% per year).

High Growth Revenue: HZNP's revenue (14.8% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: HZNP's Return on Equity is forecast to be high in 3 years time (30.7%)


Past Performance

How has Horizon Therapeutics performed over the past 5 years?

58.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: HZNP has a large one-off loss of $84.3M impacting its March 31 2021 financial results.

Growing Profit Margin: HZNP's current net profit margins (12.8%) are lower than last year (43.1%).


Past Earnings Growth Analysis

Earnings Trend: HZNP has become profitable over the past 5 years, growing earnings by 58.3% per year.

Accelerating Growth: HZNP's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: HZNP had negative earnings growth (-52.7%) over the past year, making it difficult to compare to the Biotechs industry average (1.6%).


Return on Equity

High ROE: HZNP's Return on Equity (7.3%) is considered low.


Financial Health

How is Horizon Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: HZNP's short term assets ($1.8B) exceed its short term liabilities ($773.8M).

Long Term Liabilities: HZNP's short term assets ($1.8B) do not cover its long term liabilities ($3.2B).


Debt to Equity History and Analysis

Debt Level: HZNP's debt to equity ratio (66.9%) is considered high.

Reducing Debt: HZNP's debt to equity ratio has reduced from 88.2% to 66.9% over the past 5 years.

Debt Coverage: HZNP's debt is well covered by operating cash flow (23.8%).

Interest Coverage: HZNP's interest payments on its debt are well covered by EBIT (7.6x coverage).


Balance Sheet


Dividend

What is Horizon Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate HZNP's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate HZNP's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if HZNP's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if HZNP's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of HZNP's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

6.0yrs

Average management tenure


CEO

Tim Walbert (53 yo)

12.92yrs

Tenure

US$21,632,804

Compensation

Mr. Timothy P. Walbert, also known as Tim, has been the Chairman of the Board at Exicure, Inc. since April 2020 and has been its Independent Director since July 22, 2019. Mr. Walbert served as Lead Indepen...


CEO Compensation Analysis

Compensation vs Market: Tim's total compensation ($USD21.63M) is above average for companies of similar size in the US market ($USD11.15M).

Compensation vs Earnings: Tim's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.


Leadership Team

Experienced Management: HZNP's management team is seasoned and experienced (6 years average tenure).


Board Members

Experienced Board: HZNP's board of directors are considered experienced (7.1 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: HZNP insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 17.8%.


Top Shareholders

Company Information

Horizon Therapeutics Public Limited Company's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Horizon Therapeutics Public Limited Company
  • Ticker: HZNP
  • Exchange: NasdaqGS
  • Founded: 2005
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$19.721b
  • Shares outstanding: 224.77m
  • Website: https://www.horizontherapeutics.com

Number of Employees


Location

  • Horizon Therapeutics Public Limited Company
  • Connaught House
  • 1st Floor
  • Dublin
  • Co. Dublin
  • 4
  • Ireland

Listings


Biography

Horizon Therapeutics Public Limited Company focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and int...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/05/13 23:46
End of Day Share Price2021/05/13 00:00
Earnings2021/03/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.